

Alessandro Ciresi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5928976/publications.pdf>

Version: 2024-02-01

52
papers

1,063
citations

430874

18
h-index

454955

30
g-index

53
all docs

53
docs citations

53
times ranked

1435
citing authors

#	ARTICLE	IF	CITATIONS
1	Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. <i>Clinical Endocrinology</i> , 2013, 79, 845-852.	2.4	69
2	Diabetes Secondary to Acromegaly: Physiopathology, Clinical Features and Effects of Treatment. <i>Frontiers in Endocrinology</i> , 2018, 9, 358.	3.5	68
3	Metabolic parameters and adipokine profile during GH replacement therapy in children with GH deficiency. <i>European Journal of Endocrinology</i> , 2007, 156, 353-360.	3.7	67
4	Is diabetes in Cushing's syndrome only a consequence of hypercortisolism?. <i>European Journal of Endocrinology</i> , 2014, 170, 311-319.	3.7	60
5	Hyperinsulinism and polycystic ovary syndrome (PCOS): role of insulin clearance. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 1319-1326.	3.3	59
6	Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS. <i>PLoS ONE</i> , 2017, 12, e0186136.	2.5	59
7	The Metabolic Profile in Active Acromegaly is Gender-Specific. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E51-E59.	3.6	54
8	Visceral Adiposity Index Is Associated with Insulin Sensitivity and Adipocytokine Levels in Newly Diagnosed Acromegalic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2907-2915.	3.6	51
9	Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. <i>Pituitary</i> , 2012, 15, 539-551.	2.9	34
10	Corneal acromegalic patients as a possible target of growth hormone action. <i>Journal of Endocrinological Investigation</i> , 2011, 34, e30-e35.	3.3	33
11	The degree of urinary hypercortisolism is not correlated with the severity of Cushing's syndrome. <i>Endocrine</i> , 2017, 55, 564-572.	2.3	32
12	Vitamin D across growth hormone (GH) disorders: From GH deficiency to GH excess. <i>Growth Hormone and IGF Research</i> , 2017, 33, 35-42.	1.1	31
13	No Phenotypic Differences for Polycystic Ovary Syndrome (PCOS) Between Women With and Without Type 1 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 203-211.	3.6	27
14	Lacrimal gland herniation in Graves ophthalmopathy: a simple and useful MRI biomarker of disease activity. <i>European Radiology</i> , 2020, 30, 2138-2141.	4.5	24
15	High prevalence of hypovitaminosis D in Sicilian children affected by growth hormone deficiency and its improvement after 12 months of replacement treatment. <i>Journal of Endocrinological Investigation</i> , 2014, 37, 631-638.	3.3	23
16	Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment: a 36-month retrospective analysis. <i>Clinical Endocrinology</i> , 2018, 88, 665-672.	2.4	23
17	Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency. <i>Endocrine Connections</i> , 2019, 8, 853-862.	1.9	23
18	Reduction in insulin sensitivity and inadequate β -cell capacity to counteract the increase in insulin resistance in children with idiopathic growth hormone deficiency during 12 months of growth hormone treatment. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 351-359.	3.3	21

#	ARTICLE	IF	CITATIONS
19	Predictors of microvascular complications in type 1 diabetic patients at onset: The role of metabolic memory. <i>European Journal of Internal Medicine</i> , 2011, 22, 266-274.	2.2	19
20	Resistin, visfatin, leptin and omentin are differently related to hormonal and metabolic parameters in growth hormone-deficient children. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 1023-1030.	3.3	17
21	Serum visfatin levels in acromegaly: Correlation with disease activity and metabolic alterations. <i>Growth Hormone and IGF Research</i> , 2015, 25, 240-246.	1.1	16
22	Pasireotide treatment reduces cardiometabolic risk in Cushing's disease patients: an Italian, multicenter study. <i>Endocrine</i> , 2018, 61, 118-124.	2.3	16
23	Glycometabolic control in acromegalic patients with diabetes: a study of the effects of different treatments for growth hormone excess and for hyperglycemia. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 154-9.	3.3	16
24	OCT is not useful for detection of minimal diabetic retinopathy in type 1 diabetes. <i>Acta Diabetologica</i> , 2010, 47, 259-263.	2.5	15
25	Revaluation of the clinical and metabolic behavior of children with isolated growth hormone deficiency during GH treatment according to newly proposed note 39 of the Italian Medicines Agency (AIFA). <i>Journal of Endocrinological Investigation</i> , 2015, 38, 1301-1307.	3.3	15
26	Alteration of the growth hormone axis, visceral fat dysfunction, and early cardiometabolic risk in adults: the role of the visceral adiposity index. <i>Endocrine</i> , 2015, 49, 492-502.	2.3	14
27	Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing's disease. <i>Endocrine</i> , 2018, 62, 207-214.	2.3	14
28	The visceral adiposity index is associated with insulin sensitivity and IGF-I levels in adults with growth hormone deficiency. <i>Endocrine</i> , 2017, 56, 579-588.	2.3	13
29	Hepatic Steatosis Index in Acromegaly: Correlation with Insulin Resistance Regardless of the Disease Control. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-7.	1.5	13
30	Adrenal morphology and function in acromegalic patients in relation to disease activity. <i>Endocrine</i> , 2009, 36, 346-354.	2.3	10
31	Growth hormone and hematopoiesis: A retrospective analysis on a large cohort of children with growth hormone deficiency. <i>Growth Hormone and IGF Research</i> , 2018, 42-43, 8-13.	1.1	10
32	Corneal thickness in children with growth hormone deficiency: The effect of GH treatment. <i>Growth Hormone and IGF Research</i> , 2014, 24, 150-154.	1.1	9
33	Early Lung Function Abnormalities in Acromegaly. <i>Lung</i> , 2015, 193, 393-399.	3.3	9
34	Glucose Metabolism in Children With Growth Hormone Deficiency. <i>Frontiers in Endocrinology</i> , 2018, 9, 321.	3.5	9
35	Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report. <i>BMC Endocrine Disorders</i> , 2018, 18, 2.	2.2	9
36	Circulating Irisin Levels in Children With GH Deficiency Before and After 1 Year of GH Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 801-808.	3.6	9

#	ARTICLE	IF	CITATIONS
37	The Daily Consumption of Cola Can Determine Hypocalcemia: A Case Report of Postsurgical Hypoparathyroidism-Related Hypocalcemia Refractory to Supplemental Therapy with High Doses of Oral Calcium. <i>Frontiers in Endocrinology</i> , 2017, 8, 7.	3.5	8
38	Insulin sensitivity and secretion and adipokine profile in patients with Cushing's disease treated with pasireotide. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 1137-1147.	3.3	8
39	Utility of C-peptide for a reliable estimate of insulin secretion in children with growth hormone deficiency. <i>Growth Hormone and IGF Research</i> , 2016, 29, 71-77.	1.1	7
40	Comparison between euglycemic hyperinsulinemic clamp and surrogate indices of insulin sensitivity in children with growth hormone deficiency. <i>Growth Hormone and IGF Research</i> , 2018, 39, 40-44.	1.1	7
41	Higher cardiometabolic risk in idiopathic versus autoimmune type 1 diabetes: a retrospective analysis. <i>Diabetology and Metabolic Syndrome</i> , 2018, 10, 40.	2.7	7
42	More Favorable Metabolic Impact of Three-Times-Weekly versus Daily Growth Hormone Treatment in Naïve GH-Deficient Children. <i>International Journal of Endocrinology</i> , 2017, 2017, 1-8.	1.5	5
43	Pasireotide versus pituitary surgery: a retrospective analysis of 12 months of treatment in patients with Cushing's disease. <i>Endocrine</i> , 2018, 59, 454-457.	2.3	5
44	Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study. <i>Diabetes Therapy</i> , 2018, 9, 363-371.	2.5	5
45	Correlation between Severity of Growth Hormone Deficiency and Thyroid Metabolism and Effects of Long-Term Growth Hormone Treatment on Thyroid Function in Children with Idiopathic Growth Hormone Deficiency. <i>Hormone Research in Paediatrics</i> , 2014, 81, 379-385.	1.8	3
46	Direct and indirect effects of Growth Hormone Deficiency (GHD) on lung function in children: A mediation analysis. <i>Respiratory Medicine</i> , 2018, 137, 61-69.	2.9	3
47	One-hour post-load plasma glucose level is associated with a worse metabolic profile in children with GH deficiency. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 789-797.	3.3	3
48	Correlation between adrenal function, growth hormone secretion, and insulin sensitivity in children with idiopathic growth hormone deficiency. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 333-342.	3.3	3
49	The metabolic outcomes of growth hormone treatment in children are gender specific. <i>Endocrine Connections</i> , 2018, 7, 879-887.	1.9	3
50	Improved Cardiovascular and Cardiometabolic Risk in Patients With Type 1 Diabetes and Autoimmune Polyglandular Syndrome Switched From Glargine to Degludec Due to Hypoglycaemic Variability. <i>Frontiers in Endocrinology</i> , 2018, 9, 428.	3.5	2
51	Relative Hypoleptinemia in Poorly Controlled Patients with Type 1 Diabetes. <i>Hormone and Metabolic Research</i> , 2007, 39, 398-399.	1.5	1
52	Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia in acromegaly with severe visceromegaly and divergence between growth hormone and insulin-like growth factor-1 concentrations during the follow-up: causal or casual association?. <i>Growth Hormone and IGF Research</i> , 2012, 22, 92-96.	1.1	1